Saturday, July 31, 2021
Friday, July 30, 2021
The proposed over 100 acres landscape for the Trichy long- felt Super model Integrated Bus Terminal at Panjappur in @TrichyCorp. With the constant continuous efforts of our Municipal minister @KN_NEHRU is expecting the Fund allotment in the Tamilnadu full Budget 2021-22 for this new mega project in Trichy city - 29.7.21 M.A.Aleem Swachh Bharat Ambassador Trichy
Wednesday, July 28, 2021
Monday, July 26, 2021
Sunday, July 25, 2021
World war one Arch at Valady Need Attention - M.A.Aleem Neurologist #Trichy Member Tiruchirappalli District Welfare Fund Committee
World war one Arch at Valady Need Attention
- M.A.Aleem Neurologist #Trichy Member Tiruchirappalli District Welfare Fund Committee
A 98 years old World War one memorial arch at Valady village in Tiruchirappalli District, which is lying in ruins, has the words “Lest We Forget” written on its peak. Considering the state in which it’s languishing in, one can’t help but feel a palpable sense of irony.
This commemorative arch erected near Valady in Trichy during the British rule,in August 8, 1922 in recognising the role of Indian soldiers in the victory of the Allied powers in World War I, is in the state of ruining now. It is feared now that the 98-year-old structure could crumble any time even before its 100th anniversary if the rain fall intensifies.
As with many historic structures, the right portion of the arch is being encroached upon by a shop and bricks have been coming out one by one.
This arch opened by Sir T. Desikachariar, Trichinopoly District Board president, on August 10, 1922.
This need uplift in this 71st year Republic day sir - M.A.Aleem Neurologist Trichy Tamilnadu India .
My request send to January 2020 Mann ki batt and to Trichy Collector on27.1 20
Saturday, July 24, 2021
How to Get Ready for CAA, NPR & NRC
CAA, NPR & NRC பற்றி மிக, மிக துல்லியமாக, தெளிவாக விளக்கம்.
1955 குடியுரிமை சட்டப்படி ஒருவர் இந்தியர் என்பதைச் சட்ட ரீதியாக உறுதிபடுத்துவது எப்படி?
கீழ்கண்டவாறு ஒவ்வொருவரும் செய்யுங்கள்:
1. வீட்டிலுள்ள அனைவரின் பிறந்த தேதி எழுதி கொள்ளுங்கள்.
2. அதனை மூன்று கேட்டகரியாக பிரியுங்கள்.
அ. 1987 ஜூலை 1 ஆம் தேதிக்கு முன்னர் பிறந்தவர்கள்
ஆ. 1987 ஜூலை 1 க்கும் 2004 டிசம்பர் 31 க்கும் இடையில் பிறந்தவர்கள்
இ. 2004 டிசம்பர் 31 க்குப் பின்னர் பிறந்தவர்கள்
3. இதில், 1987 ஜூலை 1 க்கு முன்னர் பிறந்தவர்களுக்குப் பிறப்பு சான்று அல்லது பாஸ்போர்ட் ஆகிய இரண்டில் ஒன்று இருப்பதை உறுதிபடுத்துங்கள். எனில், இவர்கள் பிறப்பின் அடிப்படையில் நேரடியாக இந்தியர்கள். வேறு எந்தச் சான்றும் தேவையில்லை.
4. 1987 ஜூலை 1 க்குப் பின்னர் பிறந்தவர்கள் அனைவருக்கும் பிறப்புச் சான்றிதழ் இருக்கிறதா என உறுதிபடுத்துங்கள். இருக்கிறது எனில்,
அ. 1987 ஜூலைக்கும் 2004 டிசம்பருக்கும் இடையில் பிறந்தவர்கள் பெற்றோரில் யாராவது ஒருவர் இந்தியர் என்பதை உறுதிபடுத்துங்கள். அதாவது அவர்களின் பெற்றோரில் யாராவது ஒருவர் பிறப்பு சான்று அல்லது பாஸ்போர்டில் இருக்கும் பெயர் அவர்களின் பிறப்பு சான்றிதழில் இருப்பது போல் இருக்கிறதா என்பதை உறுதி படுத்துங்கள். எனில், இவர்களும் வம்சாவழி அடிப்படையில் இந்தியர். வேறு சான்று தேவையில்லை.
2004 டிசம்பருக்குப் பின்னர் பிறந்தோரின் பெற்றோர் இருவருமே இந்தியராகவும் அவர்களின் சான்றில் பெயர்கள் சரியாக ஒத்துப்போகவும் வேண்டும். எனில், இவர்களும் வம்சாவழியில் இந்தியர். வேறு சான்று தேவையில்லை.
மேற்கண்ட அடிப்படையில் ஒவ்வொருவரும் அவரவர் வீட்டில் செக் செய்து, பாஸ்போர்ட் அல்லது பிறப்புச் சான்று இல்லாதவர் லிஸ்ட் எடுத்துக் கொள்ளுங்கள்.
பாஸ்போர்ட் எடுக்க, ஏதேனும் ஆதார்/ரேசன் கார்டு ஏதாவது சப்மிட் செய்து பாஸ்போர்ட் எடுங்கள். இது எளிது.
பிறப்புச் சான்று எனில்,
1. மருத்துவமனையில் பிறந்தவராக இருந்தால், அந்த மருத்துவமனை இருக்கும் ஏரியா கிராம/தாலுகா/கார்ப்பரேசன் அலுவலகத்துக்குச் சென்று விவரம் கூறி அப்ளை செய்யுங்கள். 200 ரூபாய்தான் செலவு. இலகுவாக கிடைக்கும்.
2. வீட்டில் பிறந்தவராக இருந்தால்,
பிறப்பு சான்று இல்லை என்பதற்கு ஒரு அஃபிடவிட் நோட்டரி அட்டஸ்டேசனுடன் தயார் செய்து உங்கள் கிராம/தாலுக்/கார்ப்பரேசன் அலுவலகத்தில் சப்மிட் செய்யுங்கள். அவர்கள் பிறப்பு சான்று இல்லை என்பதற்கான ஒரு சான்று தருவர். அதனைக் கொண்டு மாவட்ட நீதிமன்றத்தில் சப்மிட் செய்யுங்கள். அபராதம் கட்டச் சொல்வார்கள். ஆண்டுக்கு 200 ரூபாய். கிடைத்துவிடும்.
அவ்வளவுதான்.
இம்முறையில் அவரவர் வீட்டில் ஓகே ஆகி விட்டால், குறைந்தது ஒரு வீட்டுக்காவது இதனைச் செய்ய உதவுங்கள். அவர்களிடமும் இதையே வேறு ஒருவருக்குச் செய்ய கேளுங்கள். சமுதாயத்தில் ஒருவர்கூட விட்டுப்போகாமல் அனைவருக்கும் இந்தியர் என்பதற்கான சட்ட ஆவணம் உருவாக்கிவிடலாம் .
Friday, July 23, 2021
COVID-19 Variants of Concern (VoC) in India - M.A.Aleem BMJ 2021;374:n1821
BMJ
News
Seven days in medicine: 14-20 July 2021
BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n1821 (Published 22 July 2021)
Cite this as: BMJ 2021;374:n1821
Re: Seven days in medicine: 14-20 July 2021
Dear Editor
COVID-19 Variants of Concern (VoC) in India
In India, current COVID-19 cases are declining and it is around 28 daily cases per million population.
At present the active COVID-19 cases are 1.36% and the COVID-19 related death rate is 1.34%.
As of 23.07.2021, in India, the total number doses of COVID-19 vaccines given were 423,417,030. Till today (23.07.2021), over 89,471,879 (6.41%) were fully vaccinated against COVID-19.
As per India's COVID-19 situation report 77 which was released on 21.07.21 by WHO, about 20,116 COVID-19 variants cases were registered in India, which includes 4107 cases of Alpha variant, 215 Beta variant, one case of Gamma variant,15,754 cases of Delta variant and 39 cases of Delta plus variant.
According to the Indian SARS-CoV-2 Genomics Consortium of Government (INSACOG), the Delta variant continues to be dominant in new COVID-19 cases across India.
There is currently no evidence of any new Delta sub-lineage variant that is of greater concern than Delta variant in India.
The other COVID-19 Variants are at a lower rate and are declining in India.
The Indian Council of Medical Research (ICMR) has confirmed that most of the clinical cases in vaccine breakthrough were infected with the Delta variant but only 9.8% cases required hospitalisation, while fatality was found to be restricted to 0.4%.
So far no cases of the Lambda variant have been reported in India.
In India, the INSACOG jointly initiated by the Union Ministry of Health and the Department of Biotechnology (DBT) with the Council for Scientific and Industrial Research (CSIR) and the ICMR, is a consortium of 28 national laboratories monitoring the genomic variations in SARS-CoV-2.
Competing interests: No competing interests
23 July 2021
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India
@drmaaleem
Fiona Godlee, Editor in Chief: Best Editor Forever. M.A.Aleem BMJ 2021;374:n1819
BMJ
News
Fiona Godlee to step down as The BMJ’s editor in chief
BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n1819 (Published 19 July 2021)
Cite this as: BMJ 2021;374:n1819
Re: Fiona Godlee to step down as The BMJ’s editor in chief
Dear Editor
Fiona Godlee, Editor in Chief: Best Editor Forever
Fiona Godlee as Editor in Chief has taken The BMJ to new heights with a higher impact factor with her more than 16 years of dedicated service in BMJ.
During this period the facts in medical science were taken by BMJ to every part of the world to help people with the best health care.
Her service during this COVID-19 pandemic helped the Medical fraternity to fight COVID-19 with the best health care.
Fiona Godlee will always be remembered in Medical journalism as the best Editor in Chief forever.
Competing interests: No competing interests
23 July 2021
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India
@drmaaleem
Thursday, July 22, 2021
“It is happy to note that K.N. Nehru, Minister for Municipal Administration, had conducted review meetings on the progress of the projects. The resources of Smart City Mission must be tapped well to transform Tiruchi as a model city on various aspects of civic and basic infrastructure,” - M.A.Aleem Member Tiruchirappalli District Welfare Fund Committee comment on smart city in Trichy the Hindu in 23.07.2021
Tiruchi’s Smart City projects move at a snail’s pace https://www.thehindu.com/todays-paper/tp-national/tp-tamilnadu/tiruchis-smart-city-projects-make-slow-progress/article35481019.ece
TAMILNADU
Tiruchi’s Smart City projects move at a snail’s pace
C. Jaisankar
TIRUCHI, JULY 23, 2021 00:00 IST
UPDATED: JULY 23, 2021 06:11 IST
Though implementation of the proposals got off to a good start, they did not make progress due to various reasons
The slow progress of smart city projects has caused concern among residents of Tiruchi.
While Chennai, Coimbatore and Madurai were selected for Smart City Mission in 2016, Tiruchi got its place in the next list released by the Ministry of Housing and Urban Affairs (MoHUA) in 2017. Tiruchi is among the 11 cities in the State, which made it to the list of Smart Cities Mission.
It took nearly a year for the Corporation to short-list the projects to be taken up under the mission. The civic body finally unveiled a set of projects in 2018 after getting clearances from the State government.
The Rockfort Tourism Development Project and the Uyyakondan River Front Development Project were among the first projects unveiled.
The civic body subsequently came up with a few more proposals including the remodeling of Chathiram Bus Stand and construction of a commercial complex at Thillai Nagar.
Though the implementation of the projects got off to a good start in the beginning, they did not make progress as expected due to various reasons.
According to sources, about 20 projects are under progress in the city. But, it is said that most of the projects have been making slow progress.
The Uyyakondan River Front Development Project and the re-modelling of Chathiram Bus Stand, which were supposed to have been completed much earlier, have just now reached the final stages of construction.
The Rockfort Tourism Development Project has not been taken off.
The slow pace of implementation of the projects reflected in the recent declaration of Smart Cities ranking awards for 2020 announced by the Ministry of Housing and Urban Affairs (MoHUA) as well. The Tiruchi Corporation got none of the awards instituted by the Ministry on various heads.
“Almost five years have gone by since Tiruchi was selected for the implementation of the Smart City Mission. But, it is appalling to note that none of the major projects has been completed yet,” says N. Jamaludeen, a civic activist.
There were voices that some of the ongoing projects had not matched the motto and aims of the Smart City Mission.
M.A. Aleem, Member, District Welfare Committee, says special attention must be paid to implement all smart city proposals.
“It is happy to note that K.N. Nehru, Minister for Municipal Administration, had conducted review meetings on the progress of the projects. The resources of Smart City Mission must be tapped well to transform Tiruchi as a model city on various aspects of civic and basic infrastructure,” he adds.
@wfneurology Today to mark the #WorldBrainDay2021 July 22nd , M.A.Aleem Neurologist India COVID-19 vaccination and multiple sclerosis on 22.07.2021 in 7th #WorldBrainDay2021- M.A.Aleem Neurologist #Tamilnadu #India WORLD BRAIN DAY 2021 JULY 22nd COVID-19 VACCINATION AND MULTIPLE SCLEROSIS - M.A.ALEEM NEUROLOGIST ABC HOSPITAL TRICHY
WORLD BRAIN DAY 2021 JULY 22nd
COVID-19 VACCINATION AND MULTIPLE SCLEROSIS
- M.A.ALEEM
NEUROLOGIST
ABC HOSPITAL
TRICHY
World Federation of Neurology partners with the Multiple sclerosis (MS) International Federation to promote Multiple Sclerosis awareness on World Brain Day 2021 on July 22
"Stop Multiple Sclerosis" is the theme for the World Brain Day 2021.
Every five minutes, someone receives the life-altering diagnosis of multiple sclerosis (MS), a neurological disease that affects more than 2.8 million people of all ages worldwide.
This World Brain Day 2031 is dedicated to raising awareness for MS.
It is the need of the hour to work together to stop MS by diagnosing earlier, providing better access to life-changing treatments, and advocating for improved quality of life for those living with MS and their caregivers.
During this current COVID-19 Pandemic ,on the world brain day 2021 about Multiple Sclerosis
I would like to stress a few points about the importance of COVID-19 vaccination in the patient with MS.
GLOBAL COVID-19 ADVICE FOR PEOPLE WITH MS
COVID-19 is an illness that can affect your lungs, airways and other organs. It is caused by a novel coronavirus (called SARS-CoV-2) that has spread around the world.
This write up is based on COVID-19 vaccination in people with multiple sclerosis (MS).
ADVICE FOR PEOPLE WITH MS DURING THIS PANDEMIC
Current evidence shows that simply having MS does not make you more likely to develop COVID-19 or to become severely ill or die from the infection than the general population. However, the following groups of people with MS are more susceptible to having a severe case of COVID-19:
- People with progressive MS
- People with MS over the age of 60
- Men with MS
- Possibly South Asian people with MS
- People with higher levels of disability (for example, an EDSS score of 6 or above, which relates to needing to use a walking stick)
- People with MS and obesity, diabetes or diseases of the heart or lungs
- People taking certain disease modifying therapies for their MS .
All people with MS are advised to follow WHO guidelines for reducing the risk of infection with COVID-19.
People in the higher risk groups should pay particular attention to these measures:
- Practise social distancing by keeping at least 2 metres distance between yourself and others, to reduce your risk of infection when they cough, sneeze or speak. This is particularly important when indoors but applies to being outdoors as well.
- Make wearing a mask a normal part of being around other people and ensure that you are using it correctly by following these instructions.
- Avoid going to crowded places, especially if indoors and the room is poorly ventilated. Where this is not possible, ensure to wear a mask and practise social distancing.
- Wash your hands frequently with soap and water or an alcohol-based hand rub (70% alcohol content is considered most effective).
- Avoid touching your eyes, nose and mouth unless your hands are clean.
- When coughing and sneezing, cover your mouth and nose with a flexed elbow or tissue.
- Clean and disinfect surfaces frequently especially those which are regularly touched.
- Talk to your healthcare provider about optimal care plans, through video consultations or in-person visits where needed. Visits to health clinics/centres and hospitals should not be avoided if they are recommended based on your current health needs.
- Stay active and try to take part in activities that will enhance your mental health and well-being. Physical exercise and social activities that can take place outside and with social distancing are encouraged.
- Caregivers and family members who live with, or regularly visit, a person with MS in one of the higher risk groups should also follow these recommendations to reduce the chance of bringing COVID-19 infection into the home
COVID-19 VACCINES AND MS
First it is better to the current vaccine types and discuss vaccination timing and disease modifying therapy administration. Given the seriousness of COVID-19 – which carries a 1-3% mortality risk as well as risk for serious illness and prolonged ill-health for many – we wish to emphasise these key points:
All people with MS should be vaccinated against COVID-19 (provided that they do not have any known allergies to any of the components of the vaccines)
People with MS should be vaccinated as soon as the vaccine is available to them
Even once you have received the vaccine, it is important to follow your country’s guidelines regarding mask wearing (indoors and outdoors), social distancing, social group requirements, and hand washing.
There are several COVID-19 vaccines in use in different countries around the world, with new ones being approved regularly. Instead of assessing each vaccine individually, we have provided information below about the main types of COVID-19 vaccines in use and in development.
The spread of the SARS-CoV-2 virus spread is influenced by new COVID-19 variants and ongoing research is investigating how well the current COVID-19 vaccines protect against these new and emerging variants.
We do not know how many people in the COVID-19 vaccine clinical trials had MS, so our guidance is therefore based on data from the general population in the vaccine clinical trials, research on the effects of other types of vaccination of people with MS, and new data emerging on the safety and effectiveness of COVID-19 vaccines specifically for people with MS.
We do not know how many people in the COVID-19 vaccine clinical trials had MS, so our guidance is therefore based on data from the general population in the vaccine clinical trials, research on the effects of other types of vaccination of people with MS, and new data emerging on the safety and effectiveness of COVID-19 vaccines specifically for people with MS.
Types of COVID-19 vaccine and how they work
Vaccines work by using a part of the virus that causes the disease (such as its genetic code or ‘spike protein’), or an inactivated or weakened version of the virus, to prompt a response from the human immune system. In turn, this causes the body to produce antibodies and T-cells (a special population of white blood cells) to fight the virus, preventing it from entering and infecting other cells in the body. These vaccines do not lead to any genetic change in our bodies, will not get into the brain, and would not alter the genetic code of a foetus.
There are currently five different types of COVID-19 vaccine in use or in development that work in different ways (with examples below).
These vaccines have the genetic code for the coronavirus ‘spike’ protein made as an “mRNA” (a type of temporary genetic message), which is formulated into tiny fatty droplets for delivery. The mRNA directs production of the spike protein, which is seen and targeted by the immune system (that makes antibodies and T-cells). In this there are two vaccines:
Pfizer-BioNTech (Comirnaty)
Moderna (Moderna mRNA)
This have the genetic code for the spike protein in a viral vector. These vectors are best understood as just the shell and delivery mechanism of a virus (commonly from an adenovirus), but they lack the parts a virus needs to replicate and so can never cause an infection. Similar to mRNA vaccines, viral vector vaccines direct the production of the spike protein so that it can be seen and targeted by the immune system. They are:
AstraZeneca/Oxford (AZD1222)
Serum Institute of India (Covishield)
Gamaleya Research Institute (Gam-COVID-Vac or Sputnik V)
3.Inactivated virus vaccines
In these vaccines inactivated form of the whole coronavirus is uses. The coronavirus has been ‘killed’ so that it is unable to get into cells and replicate, and it cannot cause a COVID-19 infection. The immune system recognises the whole virus, even though it is inactivated. Which includes
Covaxin (Bharat Biotec)
Sinovac (CoronaVac)
Sinopharm (BBIBP-CorV)
Sinovac (CoronaVac)
Sinopharm (BBIBP-CorV)
4.Protein vaccines
These vaccines have the coronavirus spike protein itself (not the genetic code), along with something that boosts the immune system (an ‘adjuvant’) to ensure the spike protein is targeted.in this
• Novavax (NVX-CoV2373)
5.Live attenuated vaccines
In this vaccine a weakened, but still replicating virus. Such vaccines work by causing a mild infection in people with regular immune function. They can be dangerous in a person with a compromised immune system, so would not suitable for many people with MS, due to the way some disease modifying treatments work.
Currently (June 2021), there are no live attenuated COVID-19 vaccines in use – they are only being researched.
The following guidance refers to the mRNA, non-replicating viral vector, inactivated virus or protein COVID-19 vaccines (types 1-4 listed above).
PEOPLE WITH MS SHOULD GET A COVID-19 VACCINE
The science has shown us that the COVID-19 vaccines are safe and effective. Like other medical decisions, the decision to get a vaccine is best made in partnership with your healthcare professional. You should get a COVID-19 vaccine as soon as it becomes available to you. The risks of COVID-19 disease outweigh any potential risks from the vaccine. In addition, members of the same household and close contacts should also get a vaccine as soon as they can to maximise protection against COVID-19.
Most of the COVID-19 vaccines require two doses, and where this is the case, you need to follow your country’s guidelines on the timing of the second dose. (In some countries, you may get offered a third dose if you are categorised as having severe immunosuppression. You will need to follow your country’s guidelines on the timing of the third dose).
The Johnson & Johnson (J&J) and Sputnik v vaccine requires a single dose. Whichever vaccine you receive, it takes 2 weeks after receiving the only or second dose before you are considered immunised (protected).
If you have had COVID-19 and recovered, you should also get the vaccine, because people who have had COVID-19 infection in the past can get infected again. It is normal practice to wait until you have recovered from an illness before being vaccinated. But you should still get vaccinated as soon as you can after recovery, following the government guidelines in your country.
We do not know how long a person is protected from COVID-19 after being vaccinated, although clinical trial data indicate that protection is high for at least multiple months. Repeated doses of the COVID-19 vaccines may be required in future, similar to the flu vaccine.
There is no evidence that people with MS are at higher risk of complications from the mRNA, non-replicating viral vector, inactivated virus or protein COVID-19 vaccines , compared to the general population.
There is no vaccine preference for those living with MS.
None of the currently available vaccines contain live virus and the vaccines will not cause COVID-19 disease. These types of vaccine are not likely to trigger an MS relapse or to worsen chronic MS symptoms.
However, people with MS should avoid receiving live attenuated vaccines . Given that there may be COVID-19 vaccines developed in the future that use this technology, it is important to know which COVID-19 vaccine you are offered.
You do not need to self-isolate after the vaccination. The vaccines can cause side effects, including fever or fatigue, which should not last more than a few days after vaccination. A fever can make your MS symptoms worse temporarily, but they should return to previous levels after the fever is gone. Even if you have side effects from the first dose, it is important to get the second dose of the vaccine (for vaccines requiring two doses) for it to be fully effective. Having side effects, such as fever, muscle discomfort and fatigue are a sign that the vaccine is doing its job (it is getting your body to mount a response against the virus, and therefore is starting to protect you).
IT IS SAFE TO RECEIVE A COVID-19 VACCINE WHEN YOU ARE ON DISEASE MODIFYING THERAPIES (DMTS) FOR MS
Continue taking your disease modifying therapy (DMT) unless you are advised by your MS healthcare professional to stop or delay it. Stopping some DMTs abruptly can cause severe worsening of MS.
Some DMTs may reduce the effectiveness of the COVID-19 vaccinations
There is some evidence that people taking some types of DMT (fingolimod, siponimod, ozanimod, ponesimod, ocrelizumab, rituximab, ofatumumab) may have a reduced antibody response to the COVID-19 vaccines. The data are limited so far, but are in line with what we expect, given our understanding of these treatments.
Note that there is a range of different antibody tests that are used to measure responses to the COVID-19 vaccines. There is currently no global agreement about which antibody is the best for monitoring vaccine responses and predicting protection from COVID-19.
If you use one of these DMTs and take an antibody test it may show a low or no response. This does not mean that the vaccine is ineffective. Antibodies are only one part of the immune response to vaccination. There are other components of the immune system that are triggered by the vaccine and could contribute to your protection.
The COVID-19 vaccines may also activate T-cells, which could also protect against COVID-19. This T-cell reponse is not measured in antibody tests. However, it may be that people taking these DMTs have less protection from their vaccinations.
We strongly advise people to still get vaccinated, but be aware that you could still be vulnerable to infection and take precautions against COVID-19 infection.
Delaying the start of a DMT, or altering DMT timing, is a strategy to allow the vaccine to be fully effective
If you are able to plan when you receive your vaccine, please discuss with your MS healthcare provider how and whether to coordinate the timing of your vaccine with the timing of your DMT dose – if you are on a DMT where this is relevant . This should help ensure the vaccine is as effective as possible at generating an immune response to the coronavirus. Given the potential serious health consequences of COVID-19 disease, getting the vaccine when it becomes available to you may be more important than optimally timing the vaccine with your DMT.
Even once you have received the vaccine, it is important to continue to take precautions against COVID-19
Even when vaccinated, you can still be infected with COVID-19 and give it to others. This is even more likely for those on DMTs that might reduce the effectiveness of the vaccines (fingolimod, siponimod, ozanimod, ponesimod, ocrelizumab, rituximab, ofatumumab).
Delaying the start of a DMT, or altering DMT timing, is a strategy to allow the vaccine to be fully effective
If you are able to plan when you receive your vaccine, please discuss with your MS healthcare provider how and whether to coordinate the timing of your vaccine with the timing of your DMT dose – if you are on a DMT where this is relevant . This should help ensure the vaccine is as effective as possible at generating an immune response to the coronavirus. Given the potential serious health consequences of COVID-19 disease, getting the vaccine when it becomes available to you may be more important than optimally timing the vaccine with your DMT.
Even once you have received the vaccine, it is important to continue to take precautions against COVID-19
Even when vaccinated, you can still be infected with COVID-19 and give it to others. This is even more likely for those on DMTs that might reduce the effectiveness of the vaccines (fingolimod, siponimod, ozanimod, ponesimod, ocrelizumab, rituximab, ofatumumab).
The safest approach is to ensure that those close to you are fully vaccinated, and that you continue wearing masks, practise social distancing,wash hands and follow your country’s guidelines about getting tested for COVID-19 when necessary.
VACCINATION ADVICE FOR YOUNG PEOPLE
VACCINATION ADVICE FOR YOUNG PEOPLE
The following guidance for young people applies to vaccines currently authorised for use for this age group, and should be read together with the general advice above.
Young people aged 12-17 should be vaccinated against COVID-19
The science has shown us that the COVID-19 vaccines are safe and effective. Some countries recommend COVID-19 vaccination for all children and adolescents 12 years of age and older (who do not have ‘contraindications’ – a medical reason that prevents them from having the vaccine) using one of the COVID-19 vaccines that is authorised for this age group. Vaccination of this age group brings us one step closer to ending this pandemic and is an additional layer of protection for the most vulnerable among us.
Young people are at risk of severe illness from COVID-19
Cases of COVID-19 infection are rising in children and adolescents. While most COVID-19 infections in children and adolescents are mild, some infections are severe or even fatal. In addition to health risks due to COVID-19 infection, children and adolescents are at risk for Multisystem inflammatory syndrome in children (MIS-C) two to six weeks after infection with COVID-19. MIS-C is a condition where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. MIS-C is serious, even deadly, although with prompt and often intensive care most young people with MIS-C survive. The risks of COVID-19 and MIS-C outweigh any potential risks from the vaccine.
Young people with MS should be vaccinated against COVID-19
The importance of COVID-19 vaccination for young people with MS mirrors the advice for this age group in general, as well as the advice for adults with MS. While there is no evidence to date that young people with MS experience more severe COVID-19 infection, nor that they are at higher risk for MIS-C compared to young people who do not have MS, vaccination is strongly encouraged.
Household and family members of people with MS should be vaccinated against COVID-19
People who live in the same household as anyone with MS should also get vaccinated – including young people over the age of 12. Vaccination of an entire household reduces the risk of spreading COVID-19 between people in close contact with each other.
RECOMMENDATIONS FOR TIMING DMTS AND THE COVID-19 VACCINES
The decision of when to get the COVID-19 vaccine should include an evaluation of your risk of COVID-19, and the current state of your MS. If the risk of your MS worsening outweighs your risk of COVID-19, do not alter your DMT schedule and get the vaccine when it is available to you. If your MS is stable, consider the following adjustments in the administration of your DMT to enhance the effectiveness of the vaccine. This suggested scheduling is not always possible and getting the vaccine when it becomes available to you may be more important than timing the vaccine with your DMT. Work with your MS healthcare provider to determine the best schedule for you.
Interferons, glatiramer acetate, teriflunomide, monomethyl fumarate, dimethyl fumarate, diroximel fumarate, natalizumab
If you are about to start one of these above DMTs for the first time, do not delay starting it for your COVID-19 vaccine injection. If you are already taking one of these DMTs, no adjustments to your DMT administration are needed.
Fingolimod, siponimod, ozanimod, ponesimod
If you are about to start one of these medicines, consider getting fully vaccinated two to four weeks before starting fingolimod, siponimod, ozanimod or ponesimod. If you are already taking one of these medicines, continue taking it as prescribed and get vaccinated as soon as the vaccine is available to you.
Alemtuzumab
If you are about to start alemtuzumab, consider getting fully vaccinated at least four weeks before starting
alemtuzumab. If you are already taking alemtuzumab, consider getting vaccinated at least 24 weeks after the last alemtuzumab dose. When possible, resume alemtuzumab at least four weeks after getting fully vaccinated.
Oral cladribine
If you are about to start cladribine, consider getting fully vaccinated two to four weeks before starting cladribine. If you are already taking cladribine, the currently available limited data does not suggest that timing the vaccine in relation to your cladribine dosing is likely to make a significant difference in vaccine response. Getting the vaccine when it becomes available to you may be more important than coordinating timing of the vaccine with your cladribine treatment. If you are due for your next treatment course, when possible, resume cladribine two-four weeks after getting fully vaccinated.
Ocrelizumab, rituximab
If you are about to start ocrelizumab or rituximab, consider getting the fully vaccinated two to four weeks before starting ocrelizumab or rituximab. If you are already taking ocrelizumab or rituximab, consider getting vaccinated at least 12 weeks after the last DMT dose. When possible, resume ocrelizumab or rituximab at least 4 weeks after getting fully vaccinated*.
Ofatumumab If you are about to start ofatumumab, consider getting fully vaccinated two to four weeks before starting your DMT. If you are already taking ofatumumab, there is no data to currently guide timing of the vaccine in relation to your last DMT injection. When possible, resume ofatumumab injections two to four weeks after getting fully vaccinated.
Ofatumumab If you are about to start ofatumumab, consider getting fully vaccinated two to four weeks before starting your DMT. If you are already taking ofatumumab, there is no data to currently guide timing of the vaccine in relation to your last DMT injection. When possible, resume ofatumumab injections two to four weeks after getting fully vaccinated.
High-dose steroids
Consider getting the vaccine injection three to five days after the last dose of steroids.
Fully vaccinated = once you have received the single dose of the J&J vaccine,Sputnik v or the second dose of any other type of vaccine.
Note that vaccine protection occurs 2 weeks after the single dose of the J&J vaccine or the second dose of any other type of vaccine.
Fully vaccinated = once you have received the single dose of the J&J vaccine,Sputnik v or the second dose of any other type of vaccine.
Note that vaccine protection occurs 2 weeks after the single dose of the J&J vaccine or the second dose of any other type of vaccine.
Multiple sclerosis is caused by inflammation driven loss of myelin, a type of fat/lipid layer that insulates nerves, damaging the brain and spinal cord. Multiple sclerosis presents with an assortment of symptoms including fatigue, pain, vision issues, coordination and mobility problems as well as cognitive and emotional issues. Early diagnosis and access to proven disease-modifying treatments are vital to improving patient quality of life and significantly halting disease progression.
Along with other self protective measures COVID-19 vaccination is important to prevent COVID-19 spread.
All people with MS should be vaccinated against COVID-19 (provided that they do not have any known allergies to any of the components of the vaccines)
Wednesday, July 21, 2021
Tuesday, July 20, 2021
Monday, July 19, 2021
Dr M.A.Aleem NeurologistMember Tiruchirappalli District Welfare Fund Committee Trichy Tamilnadu India requesting our dynamic Chief minister M.K.Stalin to take step to complete and open the Zoo at Trichy
A Zoological Park at Trichy is proposed in 2009 in 153.205 Acres ( 62 Hectares) at M.R.Palayam. It is the fifth zoo under the Zoo Authority of Tamilnadu.
The first phase of the work at the proposed site was completed in 2017 with 2.4 crore. Then the state had allotted 7 crore for the next stage of zoo development.
The Central Zoo Authority had suggested some modifications for its approval. For this and the addition of more amenities, more funds are required which may around Rs 60 crore. Government should consider to complete the work of Trichy Zoo as an educational entertainment for the people of Trichy. I Dr M.A.Aleem Neurologist Trichy Tamilnadu India requesting our dynamic Chief minister M.K.Stalin to take step to complete and open the Zoo at Trichy
Sunday, July 18, 2021
India is Ahead in COVID-19 Vaccination - M.A.Aleem Neurologist Trichy in BMJ 2021;374:n1781
Bmj British Medical Journal
Editor's Choice
Caution, vaccines, testing: the only way forward
BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n1781 (Published 15 July 2021)
Cite this as: BMJ 2021;374:n1781
Rapid Response
Re: Caution, vaccines, testing: the only way forward
Dear Editor
India is Ahead in COVID-19 Vaccination
As of 16.07.2021, the total COVID-19 cases in India has crossed the total number of 31,063,987 with the single day spike of 38,112 cases along with the death rate of 1.33%.
Till yesterday (16.07.2021) about 440,023,239 samples have been collected to find out COVID-19 infection in India.
As far as COVID-19 vaccination is concerned, 395,343,767 doses against Covid-19 have so far been administered in india , with 3,878,078 people receiving the jabs in the previous 24 hours.
World Health Organization (WHO) has said that the Covid-19 pandemic is now in the “early stages” of the third wave. The Delta variant is now in more than 111 countries and it is expected that it can soon become the dominant Covid-19 strain circulating worldwide.
Although the second wave is behind us, the risk of a third wave has increased. With the presence of the Delta variant and the subsequent mutations of the virus, we consider a third wave a real risk in India.
Competing interests: No competing interests
17 July 2021
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India
@drmaaleem
Thursday, July 15, 2021
Wednesday, July 14, 2021
Tuesday, July 13, 2021
Monday, July 12, 2021
Trichy city development my Municipal minister is a good move -M.A.Aleem Nehru hints at move to expand corporations http://toi.in/eAUCjb/a24gj via @timesofindia
Trichy city development my Municipal minister is a good move -M.A.Aleem
Nehru hints at move to expand corporations http://toi.in/eAUCjb/a24gj via @timesofindia
Good initiative by Trichy @KN_NEHRU for youth - M.A.Aleem Minister announces month-long job mela - The Hindu https://t.co/dd1gpv7jQO
Good initiative by Trichy @KN_NEHRU for youth - M.A.Aleem
Minister announces month-long job mela - The Hindu https://t.co/dd1gpv7jQO
Sunday, July 11, 2021
#Trichy #Smartcity Mission : A new 10,250 Square meters three-floors fully air-conditioned commercial complex with retail outlets,foodcourts,multipurpose convention halls with two basement level parking by @TrichyCorp with the estimate of 20 crore at Puthur in under way - 10.7.21 M.A.Aleem Neurologist #Trichy #Tamilnadu #India
Saturday, July 10, 2021
Airport Advisory Committee meeting on 10.7.21 M.A.Aleem Advisory Committee Member Tiruchirappalli International Airport discussed the following point
Airport Advisory Committee meeting on 10.7.21 M.A.Aleem Advisory Committee Member Tiruchirappalli International Airport discussed the following point
1.Trichy Airport Runway Expansion
It is the long pending and must requirement for Tiruchirappalli aviation related developmentd. Because of the insufficient runway length, we are unable to plan for the commercial routes like Kuwait, Riyadh, Jeddah and Many. Imposing load restrictions, we are unable to take maximum cargo. Despite these constraints, Air India Express providing services to almost all the Gulf destinations. Indigo also doing. If runway expansion will be completed, immediately, Sri Lankan airlines, Air Asia & Scoot air will change their aircrafts to Wide body instead of existing Narrow bodied. Also Chances for Singapore airlines arrivals.
2. For export Cargo, we will have space for minimum 60 tonnes per day. It will bring minimum of 1 crore foreign remittances per day . Need more space to takle the more cargoes and get more revenue.
3.Trichy to be included in the Bilateral Air Services Agreement - BASA part*
Tiruchirappalli is not a approved service points for any Gulf countries designated carriers. Here why we are mentioning Gulf countries means, more than 50% of Indian international traffic is depending 6 Gulf countries are Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates - UAE. Our Indian Government is not allowing Gulf countries designated carriers and also Indian designated carriers are also not providing sufficient services to these Gulf countries important destinations. Now the destinations covered by Air India Express is temporary.
4.Air India Express is nearing its 1000th repatriation services . This should be honored.
5.Air traffic staffs work during COVID-19 Pandemic should be recognised and honored.
6.Good news for Trichy selected among 113 cities of india to create Pedestrian friendly streets ( Lawsons Road and Karur bypass road) in the Trichy Corporation by central Government of India under " Streets For Challenge". Airport road can also be considered as one of the choice under this scheme.
7 . The unusual delay in the completion of re-carpeting, which is an essential maintenance work being done after a gap of ten years in Trichy, has led to cancellation of flights to a few domestic destinations.
8.Air India Express (AIE) will operate a special flight from Male to Trichy on June and it should also operate from Trichy to mali .
9. AAI mooted a proposal in 2010-2011 to extend the runway length to 12,500 feet. This would enable the airport to handle wide body flight.
10.New passenger terminal building of Trichy airport to be functional from March 2022. Congratulations for their hard works
11.The project has been awarded to a Mumbai-based private company for execution, and will cost around ₹30 crore
After a gap of 10 years, the Airports Authority of India (AAI) has embarked on the task of resurfacing the runway of the Tiruchi international airport. The project has been awarded to a Mumbai-based private company for execution of the work, which will cost around ₹30 crore. This work should be speed up.
12. installing a new and upgraded Instrument Landing System (ILS) at Tiruchi International Airport to replace the existing one is expected to begin in the first week of July.
A technical team from the Radio Construction and Development Unit of Airports Authority of India (AAI) from New Delhi will carry out the installation of the ₹3.5 crore-upgraded ILS system, which will aid in smoother landing of flights at the non-metro airport.
Ahead of putting in place a new system, AAI-Tiruchi carried out civil and electrical works connected with the project. A concrete platform has been constructed at the end of Runway 27 adjoining Tiruchi-Pudukottai National Highway for installation of a set of new antennas . Congratulations for this work
13. Need adopt for a ultrasonic birds repellent method to keep flying of birds out of flying take off landing areas areas of Trichy Airport
